Brief: Vicore Pharma: Digital Therapeutic For IPF Patients

Vicore Pharma Holding AB

06/10/2022 07:24

Oct 6 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * DIGITAL THERAPEUTIC FOR IPF PATIENTS SHOWS NEARLY 50%
ANXIETY
REDUCTION IN PILOT STUDY
    * ANNOUNCES POSITIVE RESULTS FOR PILOT PHASE OF COMPANION
STUDY
    * DIGITAL COGNITIVE BEHAVIORAL THERAPY (CBT) THERAPY,
ALMEETM; FOR
PATIENTS WITH PULMONARY FIBROSIS WAS SAFE, FUNCTIONAL,
USER-FRIENDLY AND REDUCED ANXIETY SYMPTOMS BY 49% IN PATIENTS
WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
    * PRIMARY OBJECTIVE OF STUDY, TO TEST FUNCTIONALITY, USER
EXPERIENCE AND SAFETY OF DIGITAL THERAPEUTIC (DTX), WAS MET AND
PRELIMINARY EFFICACY RESULTS WERE ENCOURAGING;

Source text for Eikon:  ID:nWkr8NBG1F 
Further company coverage:  VICOR.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))